SystImmune Advances SI-B037 Into Phase 1/1b Trial
Redmond, Washington, U.S., September 22, 2026 SystImmune, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Redmond, Washington, U.S., September 22, 2026 SystImmune, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
SAN ANTONIO, Texas, April 20, 2026 Texas Biomedical Research Institute (Texas Biomed), in collaboration with the Southwest National Primate...
